Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis—results from the IBSEN III inception cohort
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18097 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Vibeke Strande and 22 co-authors. Institution: Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway. Major MEDLINE topics: Colitis, Ulcerative, Colectomy, Disease Progression, Biological Products. Cited 10 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Stiftelsen Dam, Ferring Pharmaceuticals, South-Eastern Health Authorities in Norway.
Abstract (original language)
Background
The introduction of biologic therapies and the ‘treat‐to‐target’ treatment strategy may have changed the disease course of ulcerative colitis (UC).
Aims
To describe the early disease course and disease outcome at 1‐year follow‐up in a population‐based inception cohort of adult patients with newly diagnosed UC.
Methods
The Inflammatory Bowel Disease in South‐Eastern Norway (IBSEN) III study is a population‐based inception cohort study with prospective follow‐up. Patients newly diagnosed with inflammatory bowel disease during 2017–2019 were included. Patients ≥18 years at diagnosis of UC who attended the 1‐year follow‐up were investigated. We registered clinical, endoscopic and demographic data at diagnosis and 1‐year follow‐up.
Results
We included 877 patients with UC (median age 36 years (range: 18–84), 45.8% female). At diagnosis, 39.2% presented with proctitis, 24.7% left‐sided colitis and 36.0% extensive colitis. At the 1‐year follow‐up, 13.9% experienced disease progression, and 14.5% had received one or more biologic therapies. The colectomy rate was 0.9%. Steroid‐free clinical remission was observed in 76.6%, and steroid‐free endoscopic remission in 68.7%. Anaemia and initiation of systemic steroid treatment at diagnosis were associated with biologic therapy within the first year after diagnosis.
Conclusion
In this population‐based inception cohort, colectomy rate in the first year after diagnosis was low, and a high proportion of patients were in remission at 1‐year follow‐up. The use of biologic therapy increases, consistent with findings from previous studies.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Department of Public Health, Oslo Metropolitan University, Oslo, Norway.
- Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.
- Department of Gastroenterology, Vestfold Hospital Trust, Tønsberg, Norway.
- Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway.
ORCID profiles: Vibeke Strande, Trond Espen Detlie
Funding
- Stiftelsen Dam
- Ferring Pharmaceuticals
- South-Eastern Health Authorities in Norway
- Takeda Pharmaceutical Company
- Tillotts Pharma
- Pfizer
- Ferring
Cite
APA
Strande, V., Lund, C., Hagen, M., Bengtson, M. B., Cetinkaya, R. B., Detlie, T. E., Frigstad, S. O., Høie, O., Medhus, A. W., Henriksen, M., Aass Holten, K. I., Hovde, Ø., Huppertz-Hauss, G., Johansen, I., Olsen, B. C., Opheim, R., Ricanek, P., Torp, R., Tønnessen, T., …, & Kristensen, V. A. (2024). Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis—results from the IBSEN III inception cohort. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18097
Vancouver
Strande V, Lund C, Hagen M, Bengtson MB, Cetinkaya RB, Detlie TE, et al. Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis—results from the IBSEN III inception cohort. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18097
BibTeX
@article{Strande2024,
author = {Strande, Vibeke and Lund, Charlotte and Hagen, Milada and Bengtson, May-Bente and Cetinkaya, Raziye Boyar and Detlie, Trond Espen and Frigstad, Svein Oskar and Høie, Ole and Medhus, Asle W and Henriksen, Magne and Aass Holten, Kristina I and Hovde, Øistein and Huppertz-Hauss, Gert and Johansen, Ingunn and Olsen, Bjørn Christian and Opheim, Randi and Ricanek, Petr and Torp, Roald and Tønnessen, Tor and Vatn, Simen and Aabrekk, Tone Bergene and Høivik, Marte Lie and Kristensen, Vendel A},
title = {Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis—results from the IBSEN III inception cohort},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18097}
}
EUVIMED